多柔比星耐药性急性髓系白血病AML外泌体miR-92b-5p调节N4BP1以增强PTEN的单泛素化
核心信息
- 论文英文标题: Exosomal miR-92b-5p regulates N4BP1 to enhance PTEN mono-ubiquitination in doxorubicin-resistant AML
- 期刊: Cancer Drug Resist
- 发表年份: 2025
- DOI: 10.20517/cdr.2024.140
- PMID/PMCID: 40201312; PMC11977356
研究概览
Aim: Doxorubicin, pivotal for acute myeloid leukemia (AML) treatment, often succumbs to resistance, impeding therapeutic success. Conclusion: Our study reveals a novel mechanism of doxorubicin resistance mediated by exosomal miR-92b-5p and provides potential therapeutic targets for overcoming drug resistance in AML.
核心发现
Aim: Doxorubicin, pivotal for acute myeloid leukemia (AML) treatment, often succumbs to resistance, impeding therapeutic success.
Although exosomal transfer is linked to chemoresistance, the detailed role of exosomal miRNAs in doxorubicin resistance remains incompletely understood.
Methods: We employed miRNA sequencing to delineate the profile of exosomal miRNAs in doxorubicin-resistant K562/DOX cells and AML patients.
Subsequently, qPCR was utilized to scrutinize the expression of exosomal miR-92b-5p in these resistant cells and AML patients.
Echo Biotech 角色
外泌体miRNA测序分析
关联平台: Exoomics®, Research Reagents & Tools
关联服务与能力: Biofluid EV Isolation & Purification, Cell-Culture Supernatant EV Isolation & Purification, EV miRNA Profiling / Sequencing, Research Reagent / Product Supply
关联产品或试剂: Exosupur® EV Isolation/Purification Kit
参考文献
原始论文: Exosomal miR-92b-5p regulates N4BP1 to enhance PTEN mono-ubiquitination in doxorubicin-resistant AML Cancer drug resistance (Alhambra, Calif.). 2025. DOI: 10.20517/cdr.2024.140. PMID/PMCID: 40201312; PMC11977356.